Please check your internet connection and try again.
# Mylot%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520at
## Overview
Mylot%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520at (also known as ticagrelor) is an oral P2Y12 platelet inhibitor.
## Primary Indications
* **Acute Coronary Syndrome (ACS):** For the reduction of thrombotic cardiovascular events in patients with ACS (unstable angina, non-ST-elevation myocardial infarction, or ST-elevation myocardial infarction) managed medically or with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).
* **Myocardial Infarction (MI) with a History of MI:** For the reduction of the rate of cardiovascular death, MI, and stroke in patients with a history of MI.
## Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily for at least 12 months. In patients with ACS treated with PCI, maintenance therapy can be extended beyond 12 months if clinically indicated.
* **History of MI:**
* **Maintenance Dose:** 60 mg orally twice daily.
## Pediatric Dosing
Dosing in pediatric patients has not been established.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is generally recommended. However, use with caution in severe renal impairment.
* **Hepatic Impairment:** No dose adjustment is generally recommended. However, use with caution in moderate to severe hepatic impairment.
## Contraindications
* Active bleeding.
* History of intracranial hemorrhage.
* Hypersensitivity to ticagrelor or any component of the formulation.
## Adverse Effects
* **Bleeding:** The most common and serious adverse effect is bleeding (e.g., gastrointestinal, intracranial, genitourinary).
* **Dyspnea:** Shortness of breath is common and generally not due to cardiac causes.
* **Bradyarrhythmias.**
* **Cough.**
* **Diarrhea.**
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Co-administration with strong CYP3A4 inhibitors can increase ticagrelor exposure, and co-administration with strong CYP3A4 inducers can decrease ticagrelor exposure. Examples include ketoconazole, clarithromycin, rifampin, and carbamazepine.
* **Dual Antiplatelet Therapy (DAPT):** Use with aspirin (unless contraindicated) and other antiplatelet agents requires careful consideration of bleeding risk versus benefit.
* **Statins:** Ticagrelor can increase the concentration of some statins metabolized by CYP3A4 (e.g., simvastatin, atorvastatin).
* **Omeprazole:** Concomitant use may reduce ticagrelor exposure.
## Monitoring
* **Bleeding:** Monitor for signs and symptoms of bleeding.
* **Renal function:** Monitor periodically, especially in patients with severe renal impairment.
* **Hepatic function:** Monitor periodically, especially in patients with moderate to severe hepatic impairment.
## Clinical Pearls
* Ticagrelor has a faster onset and offset of action compared to clopidogrel.
* Dyspnea is a common side effect and typically does not require discontinuation, but patients should be evaluated for other causes.
* Patients taking ticagrelor should be advised to report any signs of bleeding, bruising, or unusual symptoms.
* The decision to continue ticagrelor beyond 12 months in ACS patients should be individualized based on bleeding risk and ischemic risk.
***
*This information is intended for healthcare professionals. Always consult the current prescribing information and relevant guidelines before making clinical decisions.*
